Key result
Aprocitentan at doses of 10, 25, and decreased sitting systolic and diastolic blood pressure from baseline to week 8, with placebo-corrected decreases up to 9.90/6.99 mmHg in patients with essential hypertension.
Why the study?
Does aprocitentan reduce blood pressure in patients with essential or resistant hypertension?
Does aprocitentan reduce blood pressure in patients with essential or resistant hypertension?
Aprocitentan, a dual endothelin receptor antagonist, significantly lowers blood pressure and represents a promising emerging therapy for resistant hypertension.
Answers are grounded in this paper and cite their sources.
May support resistant hypertension options; leaves open confirmation in dedicated RCTs.
Aprocitentan (ACT-132577) is an orally active, dual endothelin-1 (ET-1) receptor antagonist that prevents the binding of ET-1 to both ETA/ETB receptors. It is an active metabolite of macitentan (obtained by oxidative depropylation), an orphan drug used for the treatment of pulmonary arterial hypertension. Aprocitentan is highly bound to plasma proteins and is eliminated in both urine and feces. It is well tolerated across all doses (up to 600 mg with single dose and 100 mg once a day at multiple doses). Its pharmacokinetic profile shows a half-life of 44 h, fitting a once-daily dosing regimen with plasma ET-1 concentrations (reflecting ET receptor antagonism), significantly increasing with doses ≥ 25 mg. Only minor differences in exposure between healthy females and males, healthy elderly and adult subjects, fed and fasted conditions, and renal function have been observed. Aprocitentan in patients with resistant hypertension is currently under investigation in the PRECISION phase III trial (ClinicalTrials identifier: NCT03541174). Nonetheless, results of pre-clinical data and studies in humans support the potential role of aprocitentan in this clinical setting. The absolute blood pressure (BP) reductions with aprocitentan are in the ranges established as a surrogate for reduction in cardiovascular morbidity in hypertension. Significant changes in BP with aprocitentan are observed within 14 days, and its BP-lowering effects have also been documented with ambulatory BP monitoring. Finally, aprocitentan enhances the BP-lowering effects of other antihypertensive drugs, including renin-angiotensin-system blockers. In conclusion, aprocitentan ameliorates the effects of ET-1 and could potentially reduce BP and provide broader cardiovascular protection in patients with resistant hypertension. Available data support the hypothesis that this new agent could expand our antihypertensive arsenal in resistant hypertension, making aprocitentan an attractive candidate for further large-scale trials.
No takes yet. Share an insight, caveat, or question.
Angeli et al. (2021) conducted a review in Essential hypertension (n=490). Aprocitentan vs. Placebo or lisinopril 20 mg was evaluated on Change in sitting systolic/diastolic unattended office blood pressure from baseline to week 8 (9.90/6.99 mmHg placebo-corrected decrease (25 mg dose)). Aprocitentan at doses of 10, 25, and decreased sitting systolic and diastolic blood pressure from baseline to week 8, with placebo-corrected decreases up to 9.90/6.99 mmHg in patients with essential hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: